Ann: Neurizon updates on NUZ-001 IND Application, page-428

"Hopefully Neurizon will learn from this event."

No, Neurizon is across all of that talkfest content.

Good to see the usual suspects collaborating on attracting more pharma business into Mass General,

but far more interesting to see multiple pharma representatives from Biogen, Amylyx, Novartis etc. actively contributing,

as well as reps from the ALS Investment Fund and Venture Capital companies.

And passively lurking, a whole bunch of biotechs and big pharma catching up on deals, industry gossip and FDA shenanigans:

Acelot, Alethia Neuroenergetics, Athira Pharma, Atom Therapeutics, Brainstorm Cell Therapeutics, Bruce McCarthy Consulting, Cellavita, Cellenkos, Denali Therapeutics, Eli Lilly & Company, Insmed, Korro Bio, Klotho Neurosciences, MarvelBiome, Mitochon Pharmaceuticals, Mitsubishi Tanabe Pharma America, Myrobalan, Neurizon Therapeutics, QurAlis, Scholar Rock, SIRONAX, Sundgreen Consulting, Third Rock Ventures, uniQure, Verge Genomics, Woolsey Pharmaceuticals, and Zydus Therapeutics. That's happening next week.

https://www.eventbrite.com/e/neals-workshop-on-advancing-als-clinical-trials-registration-1092597993009

News on the way…

cheers,

Ice